European register of patients with sickle cell disease treated with hydroxyurea is being set upBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7157.541a (Published 22 August 1998) Cite this as: BMJ 1998;317:541
- Sally C Davies, Director of research and development,
- Marilyn Roberts-Harwood, Research registrar
- NHS Executive North Thames Regional Office, London W2 3QR
- Department of Haematology, Central Middlesex Hospital, London NW10 7NS
EDITOR—In 1995 Charache et al showed conclusively in the United States that hydroxyurea ameliorates the clinical consequences of sickle cell disease in most patients.1There is no biological reason to expect greatly different results in Britain. Moreover, there has not been any serious discussion at any meetings of European or North American experts that has been in support of repeating the study. Doing so is not warranted from either the research or cost perspectives.
We were therefore surprised to read the editorial by Olujohungbe …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial